The number of non-surgical cosmetic procedures continues to rise year after year. With procedures that require little or no downtime, the trend will undoubtedly continue to escalate. In recent years, injectable botulinum toxin type A treatments have become the single largest cosmetic procedure in the United States, and now, a new topical (needle-free!) botulinum gel named RT001 has been developed and is currently going through FDA trials.
Revance Therapeutics, a US biopharmaceutical company, has developed a patented peptide delivery system for the treatment of crow’s feet. This system is able to transport the large botulinum toxin A molecule in gel form through the skin and to the target site. The gel is left on the skin for twenty minutes, and according to one study, good results and no major side effects were reported by 89% of the patients.
The delivery system is also being developed to carry the botulinum toxin type A to the targeted muscle in an injectable form which will potentially provide longer lasting results and also reduce the unwanted spread of the toxin to other tissues. This technology may ultimately change the way botulinum toxin is delivered to the targeted areas, which will improve the patient's experience.
Once RT001 receives FDA approval, the gel will be available by prescription for use in a doctor’s office. Welcome news for those who are looking for a safe, more natural looking aesthetic result without needles!
No comments:
Post a Comment